Nitrogen-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway

Biochemical Pharmacology

Volumn 85, Issue 2, 2013, Pages 163-172

  Tsubaki, Masanobu ^a   Itoh, Tatsuki ^b   Satou, Takao ^b   Imano, Motohiro ^b   Komai, Makiko ^a   Ogawa, Naoki ^a,c   Mukai, Junji ^c   Nishida, Shozo ^a  

^a KINKI UNIVERSITY   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Izumi Municipal Hospital   (Japan)

Author keywords

Bim; ERK1 2; mTOR; Nitrogen containing bisphosphonates; Ras

Indexed keywords

ALENDRONIC ACID; BIM PROTEIN; BISPHOSPHONIC ACID DERIVATIVE; CASPASE 3; CASPASE 9; GERANYLGERANYL PYROPHOSPHATE; INCADRONIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; MINODRONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; NITROGEN CONTAINING BISPHOSPHONATE DERIVATIVE; PROTEIN BCL 2; PROTEIN BCL XL; RAS PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL STRAIN HL 60; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; PRENYLATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL;

ALENDRONATE; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BONE DENSITY CONSERVATION AGENTS; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; DIPHOSPHONATES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HEMATOLOGIC NEOPLASMS; HUMANS; IMIDAZOLES; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN PRENYLATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84872030464     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.10.009     Document Type: Article

References (35)

1. J.L. Bos Ras oncogenes in human cancer: a review Cancer Res 49 1989 4682 4689
2. K. Shannon The Ras signaling pathway and the molecular basis of myeloid leukemogenesis Curr Opin Hematol 2 1995 305 308
3. S. Schubbert, K. Shannon, and G. Bollag Hyperactive Ras in developmental disorders and cancer Nat Rev Cancer 7 2007 295 308
4. K. Tobal, A. Pagliuca, B. Bhatt, N. Bailey, D.M. Layton, and G.J. Mufti Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia Leukemia 4 1990 486 489
5. H. Kiyoi, T. Naoe, Y. Nakano, S. Yokota, S. Minami, and S. Miyawaki Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia Blood 93 1999 3074 3080
6. L.R. Rohrschneider, R.P. Bourette, M.N. Lioubin, P.A. Algate, G.M. Myles, and K. Carlberg Growth and differentiation signals regulated by the M-CSF receptor Mol Reprod Dev 46 1997 96 103
7. R.J. Shaw, and L.C. Cantley Ras, PI(3)K and mTOR signalling controls tumour cell growth Nature 441 2006 424 430
8. H. Fleisch Bisphosphonates: mechanisms of action Endocr Rev 19 1998 80 100
9. H. Fujita, T. Utsumi, S. Muranaka, T. Ogino, H. Yano, and J. Akiyama Involvement of Ras/extracellular signal-regulated kinase, but not Akt pathway in risedronate-induced apoptosis of U937 cells and its suppression by cytochalasin B Biochem Pharmacol 69 2005 1773 1784
10. B. Karabulut, C. Erten, M.K. Gul, E. Cengiz, B. Karaca, and Y. Kucukzeybek Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells Cell Biol Int 33 2009 239 246
11. V. Stresing, F. Daubiné, I. Benzaid, H. Mönkkönen, and P. Clézardin Bisphosphonates in cancer therapy Cancer Lett 257 2007 16 35
12. M. Tsubaki, C. Kato, M. Nishinobo, M. Ogaki, T. Satou, and T. Ito Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits macrophage inflammatory protein 1 alpha expression and secretion in mouse myeloma cells Cancer Sci 99 2008 152 158
13. Y. Tanimori, M. Tsubaki, Y. Yamazoe, T. Satou, T. Itoh, and Y. Kidera Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits tumor metastasis in mouse melanoma through suppression of the Rho/ROCK pathway Clin Exp Metastasis 27 2010 529 538
14. M. Tsubaki, T. Satou, T. Itoh, M. Imano, M. Ogaki, and M. Yanae Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway Toxicol Appl Pharmacol 259 2012 402 410
15. S. Nishida, Y. Fujii, S. Yoshioka, S. Kikuichi, M. Tsubaki, and K. Irimajiri A new bisphosphonate, YM529 induces apoptosis in HL60 cells by decreasing phosphorylation of single survival signal ERK Life Sci 73 2003 2655 2664
16. P.J. Casey, and M.C. Seabra Protein prenyltransferases J Biol Chem 271 1996 5289 5292
17. S.J. McTaggart Isoprenylated proteins Cell Mol Life Sci 63 2006 255 267
18. T. Iguchi, Y. Miyakawa, K. Yamamoto, M. Kizaki, and Y. Ikeda Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway Cell Signal 15 2003 719 727
19. S. Nishida, S. Kikuichi, H. Haga, S. Yoshioka, M. Tsubaki, and K. Fujii Apoptosis-inducing effect of a new bisphosphonate, YM529, on various hematopoietic tumor cell lines Biol Pharm Bull 26 2003 96 100
20. C.M. Shipman, M.J. Rogers, J.F. Apperley, R.G. Russell, and P.I. Croucher Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity Br J Haematol 98 1997 665 672
21. M.V. Lee, E.M. Fong, F.R. Singer, and R.S. Guenette Bisphosphonate treatment inhibits the growth of prostate cancer cells Cancer Res 61 2001 2602 2608
22. S. Nishida, H. Matsuoka, M. Tsubaki, Y. Tanimori, M. Yanae, and Y. Fujii Mevastatin induces apoptosis in HL60 cells dependently on decrease in phosphorylated ERK Mol Cell Biochem 269 2005 109 114
23. G. Konstantinidou, E.A. Bey, A. Rabellino, K. Schuster, M.S. Maira, and A.F. Gazdar Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations Cancer Res 69 2009 7644 7652
24. J.C. Martinoy, and D.R. Green Breaking the mitochondrial barrier Nat Rev Mol Cell Biol 2 2001 63 67
25. J.M. Adams, and S. Cory The Bcl-2 protein family: arbiters of cell survival Science 281 1998 1322 1326
26. T. Shinjyo, R. Kuribara, T. Inukai, H. Hosoi, T. Kinoshita, and A. Miyajima Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors Mol Cell Biol 21 2001 854 864
27. R.M. Memmott, and P.A. Dennis Akt-dependent and -independent mechanisms of mTOR regulation in cancer Cell Signal 21 2009 656 664
28. A. Garami, F.J. Zwartkruis, T. Nobukuni, M. Joaquin, M. Roccio, and H. Stocker Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2 Mol Cell 11 2003 1457 1466
29. B.T. Navé, M. Ouwens, D.J. Withers, D.R. Alessi, and P.R. Shepherd Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation Biochem J 344 1999 427 431
30. B. Govindarajan, M.C. Mizesko, M.S. Miller, H. Onda, M. Nunnelley, and K. Casper Tuberous sclerosis-associated neoplasms express activated p42/44 mitogen-activated protein (MAP) kinase, and inhibition of MAP kinase signaling results in decreased in vivo tumor growth Clin Cancer Res 9 2003 3469 3475
31. S. Han, T.M. Santos, A. Puga, J. Roy, E.A. Thiele, and M. McCollin Phosphorylation of tuberin as a novel mechanism for somatic inactivation of the tuberous sclerosis complex proteins in brain lesions Cancer Res 64 2004 812 816
32. L. Ma, Z. Chen, H. Erdjument-Bromage, P. Tempst, and P.P. Pandolfi Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis Cell 121 2005 179 193
33. Q.W. Fan, C. Cheng, Z.A. Knight, D. Haas-Kogan, D. Stokoe, and C.D. James EGFR signals to mTOR through PKC and independently of Akt in glioma Sci Signal 2 2009 ra4
34. G. Steinert, C. Oancea, J. Roos, H. Hagemeyer, T. Maier, and M. Ruthardt Sulindac sulfide reverses aberrant self-renewal of progenitor cells induced by the AML-associated fusion proteins PML/RARα and PLZF/RARα PLoS ONE 6 2011 e22540
35. M. Alcalay, N. Meani, V. Gelmetti, A. Fantozzi, M. Fagioli, and A. Orleth Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair J Clin Invest 112 2003 1751 1761